Immunology of anti-glomerular basement membrane disease

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 3, 2002, Pages 279-286

  Salama, Alan D ^a   Pusey, Charles D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; HLA DR2 ANTIGEN; IMMUNOGLOBULIN; SYNTHETIC PEPTIDE;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; GOODPASTURE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTIBODY PRODUCTION; ENVIRONMENT; GENETICS; IMMUNOLOGY; PATHOLOGY;

ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODY FORMATION; ENVIRONMENT; HUMANS; IMMUNITY, CELLULAR; MAJOR HISTOCOMPATIBILITY COMPLEX;

EID: 0036257276     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200205000-00003     Document Type: Review

References (78)

1. Goodpasture's disease
2. Macrophages in renal inflammation
3. Anti-glomerular basement membrane disease
4. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression
5. Anti-glomerular basement membrane antibody-induced glomerulonephritis
6. Antigen restriction and IgG subclasses among anti-GBM autoantibodies
7. Immune aspects of the glomerulonephritis associated with pulmonary haemorrhage
8. Pulmonary haemorrhage and glomerulonephritis: Report of six cases and study of the renal lesion by the fluorescent antibody technique and electron microscopy
9. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies using standard techniques
10. Clinical application of a radioimmunoassay for autoantibodies to glomerular basement membrane
11. Molecular cloning of the human Goodpasture antigen demonstrates it to be the α3 chain of type IV collagen
12. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome
13. Extraglomerular distribution of immunoreactive Goodpasture antigen
14. Sera from patients with anti-GBM nephritis including Goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen α chains
15. Antiglomerular basement membrane antibody: Antibody specificity in different forms of glomerulonephritis
16. Detection of Goodpasture antigen in fractions prepared from collagenase digests of human glomerular basement membrane
17. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome
18. A single autoantigen in Goodpasture's syndrome identified by a monoclonal antibody to human glomerular basement membrane
19. Goodpasture syndrome: Localization of the epitope for the autoantibodies to the carboxyl-terminal region of the alpha 3(IV) chain of basement membrane collagen
20. Mapping B cell epitopes in Goodpasture's disease
21. Epitope mapping of anti-glomerular basement membrane (GBM) antibodies with synthetic peptides
22. Recombinant alpha-chains of type IV collagen demonstrate that the amino terminal of the Goodpasture autoantigen is crucial for antibody recognition
23. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease
24. The Goodpasture autoantigen: Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain
25. The Goodpasture autoantigen: Structural delineation of two immunologically privileged epitopes on α3(IV) chain of type IV collagen
26. The Goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain
27. Goodpasture disease: Characterization of a single conformational epitope as the target of pathogenic autoantibodies
28. Point mutations of single amino acids (AA) abolish ability of α3 NC1 domain to elicit experimental autoimmune glomerulonephritis (EAG) in rats
29. Goodpasture antigen: Expression of the full length α3(IV) chain of collagen IV and localisation of epitopes exclusively of the noncollagenous domain
30. Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen
31. Induction of anti-GBM nephritis in rats by recombinant alpha 3(IV)NC1 and alpha 4(IV)NC1 of type IV collagen
32. Expression and characterisation of recombinant rat α3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis
33. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis
34. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice
35. Treatment and prognosis in antibasement membrane antibody-mediated nephritis
36. New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity: Nonhumorally mediated glomerulonephritis in chickens
37. Transfer of experimental glomerulonephritis in chickens by mononuclear cells
38. The role of T cell differentiation on the pathogenesis of anti-GBM disease and Goodpasture syndrome
39. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes
40. Intraglomerular T cells and monocytes in nephritis: Study with monoclonal antibodies
41. T-cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathologic correlations
42. Cyclosporin A in the prevention and treatment of experimental autoimmune glomerulonephritis in the Brown Norway rat
43. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis
44. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis
45. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis
46. Goodpasture disease/anti-GBM disease is dependent on both B and T cell-mediated immunity
47. Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat
48. Strain specific responses of inbred rats on the severity of experimental autoimmune glomerulonephritis
49. Glomerulonephritis induced by recombinant collagen IV alpha3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: A potential T cell-mediated mechanism
50. Autoreactive T-cells in Goodpasture's syndrome recognise the N-terminal NC1 domain on α3 type IV collagen
51. Analysis of T cell responses to the autoantigen in Goodpasture's disease
52. T cell autoreactivity to insulin in diabetic and related non-diabetic individuals
53. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor
54. Immunologic mechanisms in multiple sclerosis
55. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1
56. Nephritogenic antibody mechanisms involving antigens within the glomerulus
57. The Goodpasture antigen is expressed in the human thymus
58. Insulin expression in human thymus is modulated by INS UNTR alleles at the IDDM2 locus
59. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes
60. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis: Implications for the design of specific immunotherapies
61. Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15
62. Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences
63. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
64. Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome
65. The HLA complex in Goodpasture's disease: A model for analyzing susceptibility to autoimmunity
66. Properties of HLA class II molecules divergently associated with Goodpasture's disease
67. Experimental autoimmune glomerulonephritis induced by homologous and isologous glomerular basement membrane in Brown Norway rats
68. Experimental autoimmune glomerulonephritis (EAG) induced by homologous and heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat
69. Segregation of experimental autoimmune glomerulonephritis as a complex genetic trait and exclusion of COL4A3 as a candidate gene
70. Fc gamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: A novel murine model for autoimmune glomerular basement membrane disease
71. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcR gamma-deficient mice
72. Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection
73. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane
74. Recurrent Goodpasture's disease
75. Binding of anti-basement membrane antibody to alveolar basement membrane after intratracheal gasoline instillation in rabbits
76. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome)
77. Renal impairment with chronic hydrocarbon exposure
78. Relationship between hydrocarbon exposure and nephropathology in primary glomerulonephritis